{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+hydrochloride+1000+mg+tablets", "query": { "intervention": "metformin hydrochloride 1000 mg tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 64, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+hydrochloride+1000+mg+tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T22:44:36.920Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01463228", "title": "A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)", "type": "DRUG" }, { "name": "B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 83, "start_date": "2011-09", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-08-22", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01463228" }, { "nct_id": "NCT01845077", "title": "Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "2x500 mg Metformin (Glumetza)", "type": "DRUG" }, { "name": "5 mg Linagliptin/1000 mg Metformin FDC", "type": "DRUG" }, { "name": "5 mg Linagliptin (Tradjenta)", "type": "DRUG" }, { "name": "3x500 mg Metformin (Glumetza)", "type": "DRUG" }, { "name": "2 x 500 mg Metformin (Glumetza)", "type": "DRUG" }, { "name": "5 mg Linagliptin/1000mg Metformin FDC", "type": "DRUG" }, { "name": "2 x 2.5 mg Linagliptin/750 mg Metformin FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 72, "start_date": "2013-05", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-08-19", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01845077" }, { "nct_id": "NCT01779362", "title": "RISE Adult Medication Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prediabetes", "Type 2 Diabetes" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Glargine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RISE Study Group", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "20 Years to 65 Years" }, "enrollment_count": 267, "start_date": "2013-04", "completion_date": "2019-08", "has_results": true, "last_update_posted_date": "2023-05-11", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 4, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01779362" }, { "nct_id": "NCT00546741", "title": "Drug Interaction With Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Male and Female Subjects" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Dapagliflozin + Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 18, "start_date": "2007-11", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-12-20", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 1, "location_summary": "Hamilton, New Jersey", "locations": [ { "city": "Hamilton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00546741" }, { "nct_id": "NCT01874080", "title": "Bioequivalence Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin/Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 56, "start_date": "2013-06", "completion_date": "2013-07", "has_results": false, "last_update_posted_date": "2015-04-23", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01874080" }, { "nct_id": "NCT03424005", "title": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "SGN-LIV1A", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Chemotherapy (Gemcitabine + Carboplatin or Eribulin)", "type": "DRUG" }, { "name": "Selicrelumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "Sacituzumab Govitecan", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib (Dose #1)", "type": "DRUG" }, { "name": "Inavolisib (Dose #1)", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" }, { "name": "Ribociclib (Dose #2)", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Inavolisib (Dose #2)", "type": "DRUG" }, { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Atirmociclib", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1132, "start_date": "2018-03-30", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 24, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03424005" }, { "nct_id": "NCT04264897", "title": "Antecedent Metabolic Health and Metformin Aging Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Aging", "Insulin Sensitivity", "Chronic Disease", "Mitochondria", "Insulin Resistance" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oklahoma Medical Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 166, "start_date": "2020-07-29", "completion_date": "2025-03-12", "has_results": true, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma • Madison, Wisconsin", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04264897" }, { "nct_id": "NCT03861767", "title": "REMAP Trial for Optimizing Surgical Outcomes at UPMC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Aging" ], "interventions": [ { "name": "Metformin ER", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Neal MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2019-04-15", "completion_date": "2022-09-23", "has_results": true, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861767" }, { "nct_id": "NCT01677299", "title": "Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "EFB0027 (metformin delayed release)", "type": "DRUG" }, { "name": "EFB0026 (metformin immediate-release)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elcelyx Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2012-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2016-09-20", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 2, "location_summary": "Tempe, Arizona • Lincoln, Nebraska", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01677299" }, { "nct_id": "NCT00778466", "title": "Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "metformin hydrochloride 1000 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranbaxy Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 32, "start_date": "2006-02", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2008-10-23", "last_synced_at": "2026-10-05T22:44:36.920Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00778466" } ] }